Acceleration of Bcr-Abl+ Leukemia Induced by Deletion of JAK2

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 May 6

PMID 24791858

Citations 7

Authors

E Grundschober

A Hoelbl-Kovacic

N Bhagwat

B Kovacic

R Scheicher

E Eckelhart

K Kollmann

M Keller

F Grebien

K U Wagner

R L Levine

V Sexl

Affiliations

Soon will be listed here.

Citing Articles

Carboplatin-Induced Thrombocytopenia through JAK2 Downregulation, S-Phase Cell Cycle Arrest and Apoptosis in Megakaryocytes.

Wu Y, Chen H, Hong W, Wei C, Pang J Int J Mol Sci. 2022; 23(11).

PMID: 35682967 PMC: 9181531. DOI: 10.3390/ijms23116290.

The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia.

Xu Y, Fang H, Chen Y, Tang Y, Sun H, Kong Z iScience. 2022; 25(3):103881.

PMID: 35243242 PMC: 8861657. DOI: 10.1016/j.isci.2022.103881.

Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.

Schwartzman O, Savino A, Gombert M, Palmi C, Cario G, Schrappe M Proc Natl Acad Sci U S A. 2017; 114(20):E4030-E4039.

PMID: 28461505 PMC: 5441776. DOI: 10.1073/pnas.1702489114.

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.

Bottos A, Gotthardt D, Gill J, Gattelli A, Frei A, Tzankov A Nat Commun. 2016; 7:12258.

PMID: 27406745 PMC: 4947169. DOI: 10.1038/ncomms12258.

The Philadelphia chromosome in leukemogenesis.

Kang Z, Liu Y, Xu L, Long Z, Huang D, Yang Y Chin J Cancer. 2016; 35:48.

PMID: 27233483 PMC: 4896164. DOI: 10.1186/s40880-016-0108-0.

References

Santos F, Kantarjian H, Jain N, Manshouri T, Thomas D, Garcia-Manero G . Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2009; 115(6):1131-6. PMC: 4081385. DOI: 10.1182/blood-2009-10-246363. View

Keil E, Finkenstadt D, Wufka C, Trilling M, Liebfried P, Strobl B . Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation. Blood. 2013; 123(4):520-9. DOI: 10.1182/blood-2013-03-492157. View

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner K . BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol. 2012; 8(3):285-93. DOI: 10.1038/nchembio.775. View

Panopoulos A, Zhang L, Snow J, Jones D, Smith A, El Kasmi K . STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood. 2006; 108(12):3682-90. PMC: 1895456. DOI: 10.1182/blood-2006-02-003012. View

Dawson M, Bannister A, Gottgens B, Foster S, Bartke T, Green A . JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009; 461(7265):819-22. PMC: 3785147. DOI: 10.1038/nature08448. View

Pardanani A, Gotlib J, Jamieson C, Cortes J, Talpaz M, Stone R . Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011; 29(7):789-96. PMC: 4979099. DOI: 10.1200/JCO.2010.32.8021. View

Wang Z, Kang Z, Zhang Y, Tse W, Bunting K . Mutation of STAT1/3 binding sites in gp130(FXXQ) knock-in mice does not alter hematopoietic stem cell repopulation or self-renewal potential. Am J Stem Cells. 2012; 1(2):146-153. PMC: 3385990. View

Park S, Wamsley H, Bae K, Hu Z, Li X, Choe S . Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS One. 2013; 8(3):e59675. PMC: 3609865. DOI: 10.1371/journal.pone.0059675. View

10.

Harry B, Eckhardt S, Jimeno A . JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opin Investig Drugs. 2012; 21(5):637-55. DOI: 10.1517/13543784.2012.677432. View

11.

Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl M . Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010; 2(3):98-110. PMC: 2906698. DOI: 10.1002/emmm.201000062. View

12.

Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle P . Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115(15):3109-17. PMC: 3953826. DOI: 10.1182/blood-2009-04-214957. View

13.

OShea J, Holland S, Staudt L . JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013; 368(2):161-70. PMC: 7604876. DOI: 10.1056/NEJMra1202117. View

14.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T . Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012; 489(7414):155-9. PMC: 3991463. DOI: 10.1038/nature11303. View

15.

Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, Dipersio J . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807. PMC: 4822164. DOI: 10.1056/NEJMoa1110557. View